


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On Apr. 26, 2006

TOWNSEND and TOWNSEND and CREW LLP

By: 

Brenda J. Dolly

PATENT
Attorney Docket No.: 015280-342100US
Client Reference No.: E-019-98/1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KASLOW et al.

Application No.: 09/554,960

Filed: February 12, 2003

For: VACCINES FOR BLOCKING
TRANSMISSION OF PLASMODIUM
VIVAX

Examiner: Lieto, Louis D.

Art Unit: 1632

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action mailed January 30, 2006, Applicants submit the attached form PTO/SB/08A and PTO/SB/08B at the Examiner's request. Copies of the references are not enclosed, as the references were previously submitted on February 12, 2003. The Examiner indicated in the Office Action that the attached cited references have been considered, but will not be listed on any resulting patent, unless the reference citations are listed in a separate listing, preferably a PTO/SB/08. Therefore, in order to have the cited references listed on any resulting patent, Applicants submit the attached PTO/SB/08A and B forms.

It is respectfully requested that the cited references be made of record and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR §1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jennifer L. Wahlsten
Reg. No. 46,226

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 415-576-0200
Fax: 415-576-0300
JLW:ath

60740598 v1



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	015280-342100US
-------	---	----	---	------------------------	-----------------

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AA	WO	89/10936	A1	11-16-1989	The United States of America as represented by the Secretary, U.S. Department of Commerce		<input type="checkbox"/>
	AB	WO	94/01552	A1	01-20-1994	The United States of America, as represented by the Secretary of the Department of Health and Human Services		<input type="checkbox"/>
	AC	WO	94/28930	A1	12-22-1994	Virogenetics Corporation		<input type="checkbox"/>
	AD	WO	95/08631	A2	03-30-1995	The Government of the United States of America, represented by the Secretary of the Department of Health and Human Services		<input type="checkbox"/>
	AE	WO	98/14472	A1	04-09-1998	The Government of the United States of America as represented by the Secretary, Department of Health and Human Services		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute MPEP Form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	015280-342100US
-------	---	----	---	------------------------	-----------------

Complete if Known

Application Number	09/554,960
Filing Date	February 12, 2003
First Named Inventor	Kaslow, David C.
Art Unit	1632
Examiner Name	Lieto, Louis D.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	AF	MENDIS, Kamini et al.; "Immune modulation of parasite transmission in <i>Plasmodium vivax</i> malaria: Anti-gamete antibodies can both block and enhance transmission"; <i>Molecular Strategies of Parasitic Invasion</i> ; pp. 417-426, 1987. Alan R. Liss, Inc.			<input type="checkbox"/>
	AG	PREMAWANSA, Sunil et al.; "Target antigens of transmission blocking immunity of <i>Plasmodium vivax</i> malaria: Characterization and polymorphism in natural parasite isolates"; <i>J. Immunol.</i> 144 (11):4376-4383 (June 1, 1990)			<input type="checkbox"/>
	AH	SNEWIN, Valerie A. et al.; "Transmission blocking immunity in <i>Plasmodium vivax</i> malaria: Antibodies raised against a peptide block parasite development in the mosquito vector"; <i>J. Exp. Med.</i> 181:357-362 (January 1995)			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.